Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 20/20 | 0.76 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18105414 | 0.94 | SLC22A12 (0.76) | SLC22A12SLC22A6SLC22A11 | |
| SCHEMBL18105599 | 0.91 | SLC22A12 (0.78) | SLC22A12 | |
| SCHEMBL18105440 | 0.87 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A11 | |
| SCHEMBL18105600 | 0.86 | SLC22A12 (0.77) | SLC22A12SLC22A6SLC22A11 | |
| SCHEMBL18105429 | 0.86 | SLC22A12 (0.77) | SLC22A12SLC22A6SLC22A11 | |
| SCHEMBL18105601 | 0.85 | SLC22A12 (0.78) | SLC22A12 | |
| SCHEMBL18105509 | 0.84 | SLC22A12 (0.77) | SLC22A12 | |
| SCHEMBL18105596 | 0.83 | SLC22A12 (0.79) | SLC22A12 | |
| SCHEMBL18105409 | 0.83 | SLC22A12 (0.77) | SLC22A12 | |
| SCHEMBL18105510 | 0.83 | SLC22A12 (0.77) | SLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3275867-B1 | PYRIDO-FUSED BICYCLIC COMPOUNDS AS URAT1 INHIBITORS FOR TREATING HYPERURICEMIA | SHANGHAI YINGLI PHARM CO LTD (CN) | 2020-06-10 | — | — | EP | disclosed |
| US-20180072678-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2018-03-15 | — | — | US | disclosed |
| US-20180072678-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI YINGLI PHARMACEUTICAL CO., LTD. (CN) | 2018-03-15 | — | — | US | disclosed |
| EP-3275867-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Yingli Pharmaceutical Co. Ltd. (CN) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016150255-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海璎黎药业有限公司 | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072678-A1 | CONDENSED RING DERIVATIVE, AND PREPARATION METHOD, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE THEREOF | URB2, UGP2, NLRP3 | SLC22A12 578/4885SLC22A6 830/4885SLC22A11 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.